Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Disease Markers
|
May 1, 1990
Elevated c-myc messenger RNA in multiple myeloma cell lines
R Fourney, M Palmer, A Ng, et al.
British Journal of Haematology
|
November 1, 1992
Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group
G P Browman, A Belch, J Skillings, et al.
Cancer Genetics and Cytogenetics
|
July 1, 1987
Cytogenetic and biological characterization of two new human plasma cell lines
L W Brox, A Belch, E Pollock, et al.
Nuclear Medicine Communications
|
October 1, 1992
Does gallium uptake in the pulmonary hila predict involvement by non-Hodgkin's lymphoma?
P E Champion, D Groshar, H R Hooper, et al.
Cancer Treatment Reports
|
October 1, 1987
Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma
K Wilson, W Shelley, A Belch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 15, 2006
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150
A Belch, C T Kouroukis, M Crump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1995
Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group
G P Browman, D Bergsagel, D Sicheri, et al.
Archives of Internal Medicine
|
June 1, 1985
A multicenter comparative trial of tobramycin and ticarcillin vs moxalactam and ticarcillin in febrile neutropenic patients
R Feld, T J Louie, L Mandell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2003
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
T Baetz, A Belch, S Couban, et al.
Veterinary Immunology and Immunopathology
|
September 4, 2007
Detection of genes with moderate effects on disease resistance using ovine mhc and resistance to nematodes as an example
M J Stear, A Belch, K Donskow-Schmelter, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Disease Markers
|
May 1, 1990
Elevated c-myc messenger RNA in multiple myeloma cell lines
R Fourney, M Palmer, A Ng, et al.
British Journal of Haematology
|
November 1, 1992
Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group
G P Browman, A Belch, J Skillings, et al.
Cancer Genetics and Cytogenetics
|
July 1, 1987
Cytogenetic and biological characterization of two new human plasma cell lines
L W Brox, A Belch, E Pollock, et al.
Nuclear Medicine Communications
|
October 1, 1992
Does gallium uptake in the pulmonary hila predict involvement by non-Hodgkin's lymphoma?
P E Champion, D Groshar, H R Hooper, et al.
Cancer Treatment Reports
|
October 1, 1987
Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma
K Wilson, W Shelley, A Belch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 15, 2006
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150
A Belch, C T Kouroukis, M Crump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1995
Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group
G P Browman, D Bergsagel, D Sicheri, et al.
Archives of Internal Medicine
|
June 1, 1985
A multicenter comparative trial of tobramycin and ticarcillin vs moxalactam and ticarcillin in febrile neutropenic patients
R Feld, T J Louie, L Mandell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2003
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
T Baetz, A Belch, S Couban, et al.
Veterinary Immunology and Immunopathology
|
September 4, 2007
Detection of genes with moderate effects on disease resistance using ovine mhc and resistance to nematodes as an example
M J Stear, A Belch, K Donskow-Schmelter, et al.
Page
of 5